TransCode Therapeutics, Inc.
RNAZTransCode Therapeutics, Inc. in brief
TransCode Therapeutics, Inc. is a listed company in the Biotechnology industry, based in Boston, Massachusetts, USA. Its market value was $3 M on 1 August 2026, which makes it the 27,383rd largest listed company in the world and the 4,464th largest in the USA on this site. It employs about 12 people. Its shares trade under the symbol RNAZ (Nasdaq).
Written from the figures on this page, so it changes when they do. Dates and sources are under Sources and freshness.
About TransCode Therapeutics, Inc.
TransCode is a clinical-stage company pioneering immuno-oncology and RNA therapeutics for treatment of high risk and advanced cancers. Our lead therapeutic product candidate is TTX-MC138, an antisense inhibitor of an oncogenic microRNA. TTX-MC138 has recently completed a Phase 1a clinical trial. In addition to other RNA-targeted product candidates, we are conducting research and development of a cancer vaccine product candidate and an oncolytic immunotherapy platform.
Polynoma Acquisition. On October 8, 2025, we entered into a Membership Interest Purchase Agreement with DEFJ, LLC, a Delaware limited liability company, pursuant to which we acquired 100% of the issued and outstanding membership interests of ABCJ, LLC, a Delaware limited liability company,. In the Acquisition, we issued 1,152.9568 shares of our Series A Non-Voting Convertible Preferred Stock to DEFJ. Each share of Series A Preferred Stock is convertible into 10,000 shares of common stock. Prior to the Acquisition, ABCJ was a wholly owned subsidiary of DEFJ and an indirect wholly owned subsidiary of CK Life Sciences Int’l., (Holdings) Inc., a listed entity on the Main Board of the Hong Kong Stock Exchange.
From the company's annual report filed with the US SEC: read the report
TransCode Therapeutics, Inc. timeline
- 2020
- •· approximateFirst filing with the US SECThe company's first electronic filing in SEC EDGAR.
- 2021
- 🔔· approximateInitial public offering on Nasdaq
Events of TransCode Therapeutics, Inc. from SEC EDGAR and the company record. Dates marked approximate come from statements without a cited source. Spotted a mistake? Use the correction form below.
Market cap history
World rank over time
Rank in USA: #5,158 (Jan 2022) · #5,759 (Dec 2022) · #5,654 (Jul 2023) · #4,656 (Jan 2024) · #2,390 (Mar 2026) · #4,158 (Aug 2026)
Key ratios
- P/E ratio
- n/m (loss)
- Price / sales
- —
- Price / book
- 0.3×
- Free cash flow yield
- -651.0%
- Net margin
- —
- Operating margin
- —
- Return on equity
- -335.2%
- Liabilities / assets
- 6.5%
- Profit per employee
- $-2.9 M
Financial history
| Fiscal year ending | Revenue | Growth | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | — | — | $-28M | $-35M | — |
| Dec 2024 | — | — | $-16M | $-17M | — |
| Dec 2023 | — | — | $-19M | $-19M | — |
| Dec 2022 | — | — | $-19M | $-18M | — |
| Dec 2021 | — | — | $-6M | $-7M | — |
| Dec 2020 | — | — | $-1M | $-2M | — |
Cash flow, debt and per share
| Fiscal year ending | Operating cash flow | Capital spending | Free cash flow | EPS (diluted) | Dividend / share |
|---|---|---|---|---|---|
| Dec 2025 | $-20M | $0M | $-20M | $-52.59 | — |
| Dec 2024 | $-13M | $0M | $-13M | $-1336.63 | — |
| Dec 2023 | $-18M | $0M | $-18M | $-3419.01 | — |
| Dec 2022 | $-16M | $0M | $-16M | $-1082.79 | — |
| Dec 2021 | $-5M | $0M | $-6M | $-0.81 | — |
| Dec 2020 | $-0M | — | — | $-0.51 | — |
Quarterly results
Latest quarter to Jun 2026: revenue —, net income $-7M. Lighter bars: fourth quarters worked out from the annual report. Trailing 12 months to Jun 2026.
SEC filings
- Oct 28, 20268-KCurrent reportOther events
- Oct 1, 20268-KCurrent reportMaterial agreement
- Sep 28, 20268-KCurrent reportOther events
- Sep 11, 20268-KCurrent reportDirectors or officers changed
- Aug 14, 202610-QQuarterly report · period to Jun 2026
- Aug 3, 20268-KCurrent reportBylaws amended
- Jul 20, 20268-KCurrent reportShareholder vote
- Jul 17, 20268-KCurrent reportBylaws amended
- Jul 2, 20268-KCurrent reportOther events
- Jun 18, 20268-KCurrent reportRegulation FD disclosure
- Jun 3, 20268-KCurrent reportOther events
- Jun 2, 2026DEF 14AProxy statement
Official filings of TransCode Therapeutics, Inc. with the US Securities and Exchange Commission.
Annual results
- Revenue
- —
- Operating income
- $-28 M
- Net income
- $-35 M
For year ending December-2025 · source: SEC filing
Balance sheet
- Total assets
- $162 M
- Total liabilities
- $11 M
- Total equity
- $10 M
As of December-2025
Top 13 institutional investors in TransCode Therapeutics, Inc.#
| # | Institution | Shares held | Change (shares) | % held | Value | Filed |
|---|---|---|---|---|---|---|
| 1 | Yorkville Advisors Global, LP | 75,786 | +56,147 (+285.90%) | 0.45% | $0 M | Nov 12, 2026 |
| 2 | Citadel Advisors LLC | 10,207 | New | 0.06% | $0 M | Nov 16, 2026 |
| 3 | Vanguard Capital Management LLC | 6,545 | 0 (0.00%) | 0.04% | $0 M | Nov 13, 2026 |
| 4 | Vanguard Fiduciary Trust Co | 2,982 | 0 (0.00%) | 0.02% | $0 M | Nov 13, 2026 |
| 5 | UBS Group AG | 2,650 | -238 (-8.24%) | 0.02% | $0 M | Nov 10, 2026 |
| 6 | Tower Research Capital LLC (TRC) | 1,746 | +1,069 (+157.90%) | 0.01% | $0 M | Nov 16, 2026 |
| 7 | Osaic Holdings, Inc. | 270 | New | 0.00% | $0 M | Nov 12, 2026 |
| 8 | Robinhood Markets, Inc. | 102 | — | 0.00% | $0 M | Nov 18, 2026 |
| 9 | Wells Fargo & Company/mn | 55 | 0 (0.00%) | 0.00% | $0 M | Nov 16, 2026 |
| 10 | SBI Securities Co., Ltd. | 12 | 0 (0.00%) | 0.00% | $0 M | Oct 22, 2026 |
| 11 | FMR LLC | 11 | -695 (-98.44%) | 0.00% | $0 M | Nov 10, 2026 |
| 12 | IFP Advisors, Inc | 8 | New | 0.00% | $0 M | Oct 16, 2026 |
| 13 | Northwestern Mutual Wealth Management Co | 1 | New | 0.00% | $0 M | Nov 13, 2026 |
Mutual funds holding TransCode Therapeutics, Inc.#
| Fund | Shares | Value | Of the company | Of the fund | Change in shares | Report |
|---|---|---|---|---|---|---|
| 🇺🇸 Fidelity Extended Market Index FundFidelity Management & Research Company LLC | 8,492 | $0 M | 0.05% | <0.01% | +47% | May 31, 2026 |
| 🇺🇸 Vanguard Extended Market Index FundThe Vanguard Group, Inc. | 6,545 | $0 M | 0.04% | <0.01% | no change | Jun 30, 2026 |
| 🇺🇸 Fidelity Series Total Market Index FundFidelity Management & Research Company LLC | 1,180 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
| 🇺🇸 Fidelity Total Market Index FundFidelity Management & Research Company LLC | 510 | $0 M | <0.01% | <0.01% | no change | May 31, 2026 |
Source: Fund portfolio reports to the SEC (Form N-PORT), CVM, Finansinspektionen and Indian fund houses · as of Jun 30, 2026. The 4 largest positions, each from the fund's newest report; report dates differ between funds. A fund family's funds are listed one by one, so one manager can appear many times.
Insider trading at TransCode Therapeutics, Inc.#
Shares bought and sold by directors, officers and 10% owners, from their SEC Form 4 filings.
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | CK Life Sciences Intl (Holdings) Inc10% owner | Conversion | +11.81 M | — | — | 12.11 M | Form 4 |
| filed | CK Life Sciences Intl (Holdings) Inc10% owner | Conversion | +2.02 M | — | — | 14.13 M | Form 4 |
| filed | Thomas A. FitzgeraldChief Financial Officer, Director | Buy | +49,350 | $0.510 | $25 K | 56,318 | Form 4 |
| filed | Robert Michael DudleyChief Executive Officer, Director | Buy | +98,000 | $0.510 | $50 K | 180,262 | Form 4 |
| filed | Robert Michael DudleyChief Executive Officer, Director | Buy | +12,000 | $2.650 | $32 K | 82,262 | Form 4 |
| filed | Robert Michael DudleyChief Executive Officer, Director | Buy | +6,607 | $2.550 | $17 K | 70,262 | Form 4 |
| filed | Robert Michael DudleyChief Executive Officer, Director | Buyamended | +19,000 | $2.760 | $52 K | 61,155 | Form 4/A |
| filed | Robert Michael DudleyChief Executive Officer, Director | Buy | +19,000 | $2.760 | $52 K | 912,114 | Form 4 |
Source: SEC Forms 4 and 5. Awards, option exercises and shares withheld for tax are listed but not counted in the totals
Markets and events: TransCode Therapeutics, Inc.#
Short interest, dividends, buybacks, splits, index changes and other events from FINRA, the SEC and the exchanges.
Stock splits: 1-for-28.01 reverse split ; 1-for-33.33 reverse split ; 1-for-1 split in the period to ; 1-for-40 reverse split ; 1-for-20 reverse split ; 1.649-for-1 split
Trading halts
- 2025-10-08 13:49 UTC, code LUDP, resumed 13:54 UTC
- 2025-10-08 13:39 UTC, code LUDP, resumed 13:44 UTC
- 2025-07-23 15:27 UTC, code LUDP, resumed 15:32 UTC
- 2025-05-14 23:50 UTC, code T3, resumed 13:00 UTC
- 2025-02-26 15:18 UTC, code LUDP, resumed 15:23 UTC
Fails to deliver
- : 17,026 shares at $1.73
- : 1,155 shares at $1.77
- : 857 shares at $1.77
- : 1,927 shares at $1.73
- : 3,289 shares at $1.68
Source: FINRA, SEC EDGAR (8-K, S-1/F-1, 424B4, XBRL, fails-to-deliver), Nasdaq Trader, Wikipedia index change tables
TransCode Therapeutics, Inc. scorecard#
Passes 1 of the 7 checks that could be worked out. Fiscal year 2025; market cap of Aug 1, 2026.
Valuationnot known
- –P/E below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
- –Price to book below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
- –Price to sales below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
- –Free cash flow yield above 5%The market cap dates from 2026-08-01, more than 60 days ago.
- –Earnings yield above the 10-year Treasury yieldThe market cap dates from 2026-08-01, more than 60 days ago.
- –The price assumes slower growth than the last three years'The market cap dates from 2026-08-01, more than 60 days ago.
Growth0 of 2
- –Revenue grew in the newest yearRevenue of the year before is not on file.
- –Revenue up more than 5% a year over three yearsRevenue of three years earlier is not on file.
- –Faster growth over three years than its peers' medianRevenue of three years earlier is not on file.
- ✗Earnings per share grew in the newest year-52.59 vs -1336.63Diluted EPS -52.59 in fiscal 2025 against -1336.63 the year before (report's currency).
- ✗Net income higher than five years earlier-$35 M-$35 M in fiscal 2025 against -$2 M in 2020.
- –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
Profitability0 of 3
- ✗Profitable in the newest year-$35 MNet income -$35 M in fiscal 2025.
- ✗Profitable in each of the last five years0 of 5Profitable in 0 of the five years to fiscal 2025.
- –Operating margin above its peers' medianNo operating margin on file.
- ✗Return on equity above 15%-833.2%-833.2% in fiscal 2025.
- –Return on invested capital above 10%No return on invested capital on file.
- –Operating margin wider than three years earlierOperating margins of three years earlier are not on file.
Financial health1 of 2
- ✓Short-term assets cover short-term liabilities6.3×Current ratio 6.30 at the end of fiscal 2025.
- –Debt below equityDebt or equity is not on file (or equity is negative).
- –Net debt below three years of EBITDANet debt to EBITDA is not on file.
- –Operating income covers interest five timesInterest expense is not on file.
- ✗Cash from operations positive in each of the last three years0 of 3Positive in 0 of the three years to fiscal 2025.
- –Altman Z-score outside the distress zoneThe Z-score's figures are not all on file.
Shareholder returnsnot known
- –Pays a dividendDividends are not on file.
- –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
- –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
- –Share count up no more than 2% in a yearShare counts of two years are not on file.
- –Dividends and buybacks above 3% of the market valueThe market cap dates from 2026-08-01, more than 60 days ago.
- –Free cash flow covers dividends and buybacksPaid out nothing in the newest year.
Worked out from the statements as filed (sec), the medians of Biotechnology, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work
TransCode Therapeutics, Inc.: financial statements#
Income statement, balance sheet and cash-flow statement as reported, newest period first.
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | FY 2025to Dec 31, 2025 | FY 2024to Dec 31, 2024 | FY 2023to Dec 31, 2023 | FY 2022to Dec 31, 2022 | FY 2021to Dec 31, 2021 | FY 2020to Dec 31, 2020 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Research and development | 13+38.3%— | 9.7−20.9%— | 12+19.9%— | 10+272%— | 2.8+868%— | 0.3—— | |
| General and administrative | 5.8−3.1%— | 6.0−16.8%— | 7.2−14.8%— | 8.4r8.4+147%— | 3.4+668%— | 0.4—— | |
| Operating expenses | 28+78.7%— | 16−19.4%— | 19+4.2%— | 19r19+203%— | 6.2+747%— | 0.7—— | |
| Operating income | −28—— | −16—— | −19—— | −19r−19—— | −6.2—— | −0.7—— | |
| Interest and finance income | 0.1+11479%— | 0.0−87.1%— | 0.0−74.1%— | 0.0+2974%— | 0.0+388%— | 0.0—— | |
| Interest expense and finance costs | 0.0−75.3%— | 0.0−52.0%— | 0.1+74.8%— | 0.0−66.4%— | 0.1−75.9%— | 0.4—— | |
| Other non-operating income (expense) | −6.5—— | −1.1−225%— | 0.9−18.4%— | 1.1r1.1—— | −0.7—— | −1.6—— | |
| Income before tax | −34—— | −17—— | — | — | — | — | |
| Income tax | 0.2—— | 0—— | 0—— | 0−100%— | 0.1—— | 0—— | |
| Net income including minority interests | −35—— | −17—— | −19—— | −18—— | −6.8—— | −2.3—— | |
| Net income attributable to shareholders | −35—— | −17—— | −19—— | −18—— | −6.8—— | −2.3—— | |
| Earnings per share, basic | -52.59—— | -1,336.63r-47.14—— | -3,419.01r-103.61—— | -1,082.79r-1.35—— | -0.81—— | -0.51—— | |
| Earnings per share, diluted | -52.59—— | -1,336.63r-47.14—— | -3,419.01r-103.61—— | -1,082.79r-1.35—— | -0.81—— | -0.51—— | |
| Shares, weighted average (basic) | 0.7+5392%— | 0.0r0.4+132%— | 0.0r0.2−66.6%— | 0.0r13−99.8%— | 8.4+81.7%— | 4.6—— | |
| Shares, weighted average (diluted) | 0.7+5392%— | 0.0r0.4+132%— | 0.0r0.2−66.6%— | 0.0r13−99.8%— | 8.4+81.7%— | 4.6—— | |
| Balance sheet | |||||||
| Cash and cash equivalents | 18+207%11.0% | 5.8+110%79.7% | 2.8−44.3%53.5% | 5.0−76.1%65.5% | 21+2415%90.8% | 0.8—78.5% | |
| Other current assets | 0.9−28.3%0.6% | 1.3−24.0%17.6% | 1.7−17.7%32.6% | 2.1+7.6%27.0% | 1.9+59491%8.3% | 0.0—0.3% | |
| Current assets | 22+210%13.5% | 7.1+59.2%97.2% | 4.5−39.6%86.2% | 7.4−67.5%97.3% | 23+2635%99.1% | 0.8—78.8% | |
| Property, plant and equipment | 0.4+619%0.2% | 0.1−57.3%0.7% | 0.1−42.1%2.3% | 0.2+1.1%2.7% | 0.2—0.9% | — | |
| Right-of-use (leased) assets | — | 0.0−92.2%0.5% | 0.5—9.3% | — | — | — | |
| Goodwill | 26—15.9% | — | — | — | — | — | |
| Other intangible assets | 114—70.4% | — | — | — | — | — | |
| Total assets | 162+2126%100% | 7.3+41.1%100% | 5.2−31.9%100% | 7.6−66.9%100% | 23+2074%100% | 1.1—100% | |
| Accounts payable | 3.5+29.0%2.2% | 2.7−11.2%37.1% | 3.1−29.8%59.0% | 4.3+73.6%57.3% | 2.5+578%10.9% | 0.4—35.0% | |
| Current liabilities | 3.5+26.1%2.2% | 2.8−20.6%38.0% | 3.5−19.7%67.5% | 4.3+71.6%57.3% | 2.5+526%11.0% | 0.4—38.4% | |
| Lease liabilities (non-current) | — | — | 0.0—0.7% | — | — | — | |
| Non-current liabilities | 7.0+7.4%4.3% | 6.5+16983%89.7% | 0.0—0.7% | — | — | 4.1—385% | |
| Total liabilities | 11+12.9%6.5% | 9.3+164%128% | 3.5−18.8%68.3% | 4.3+71.6%57.3% | 2.5−43.2%11.0% | 4.5—423% | |
| Retained earnings | −98—−60.3% | −63—−866% | −46—−898% | −28—−367% | −10—−44.9% | −3.5—−328% | |
| Shareholders' equity | 10—6.4% | −2.0−223%−27.7% | 1.6−49.4%31.7% | 3.2−84.1%42.7% | 20—89.0% | −3.4—−323% | |
| Total liabilities and equity | 162+2126%100% | 7.3+41.1%100% | 5.2−31.9%100% | 7.6−66.9%100% | 23+2074%100% | 1.1—100% | |
| Shares outstanding | 0.9+2395%— | 0.0r1.0+93.3%— | 0.0r0.6+17.2%— | 0.0r13−99.9%— | 13+178%— | 4.6—— | |
| Cash-flow statement | |||||||
| Depreciation and amortization | 0.1−15.9%— | 0.1−26.4%— | 0.1+25.2%— | 0.1+132%— | 0.0—— | 0—— | |
| Share-based compensation | 0.5−71.4%— | 1.7+64.0%— | 1.0+162%— | 0.4+113%— | 0.2+309%— | 0.0—— | |
| Cash from operating activities | −20—— | −13—— | −18—— | −16—— | −5.3—— | −0.5—— | |
| Capital expenditure | −0.0—— | −0.0—— | −0.0—— | −0.1—— | −0.3—— | — | |
| Cash from investing activities | −0.0—— | −0.0—— | −0.0—— | −0.1—— | −0.3—— | — | |
| Shares issued | 8.9−46.0%— | 16+3.1%— | 16+1124%— | 1.3—— | — | — | |
| Cash from financing activities | 32+92.2%— | 16+3.1%— | 16+265542%— | 0.0−100.0%— | 26+2185%— | 1.1—— | |
| Change in cash | 12+294%— | 3.0—— | −2.2—— | −16−179%— | 20+3107%— | 0.6—— | |
| Report | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | |
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Amounts in USD millions; per-share figures in USD; share counts in millions. Hover a figure for its filing and XBRL tag. Growth compares with the same quarter a year before; shares are of revenue (income and cash flow) or of total assets (balance sheet).
| Period | Trend | Last 12 months4 quarters to Jun 30, 2026 | Q2 FY2026to Jun 30, 2026 | Q1 FY2026to Mar 31, 2026 | Q4 FY2025to Dec 31, 2025 | Q3 FY2025to Sep 30, 2025 | Q2 FY2025to Jun 30, 2025 | Q1 FY2025to Mar 31, 2025 | Q4 FY2024to Dec 31, 2024 | Q3 FY2024to Sep 30, 2024 | Q2 FY2024to Jun 30, 2024 | Q1 FY2024to Mar 31, 2024 | Q4 FY2023to Dec 31, 2023 | Q3 FY2023to Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||||||
| Research and development | 17+80.7%— | 3.7+44.0%— | 5.1+130%— | 5.5*+50.5%— | 3.2+158%— | 2.6−16.7%— | 2.2+26.2%— | 3.6*+8.2%— | 1.2−63.3%— | 3.1—— | 1.8—— | 3.4*—— | 3.3—— | |
| General and administrative | 7.9+58.5%— | 2.5+53.2%— | 2.2+133%— | 1.8*+21.3%— | 1.4+49.3%— | 1.7−18.6%— | 1.0−37.8%— | 1.5*+98.1%— | 0.9−52.3%— | 2.0—— | 1.5—— | 0.7r0.7*—— | 2.0r2.0—— | |
| Operating expenses | 45+208%— | 6.8+60.8%— | 18+460%— | 16*+215%— | 4.6+111%— | 4.2−17.5%— | 3.2−3.6%— | 5.1*+24.3%— | 2.2−59.2%— | 5.1—— | 3.3—— | 4.1r4.1*—— | 5.3r5.3—— | |
| Operating income | −45—— | −6.8—— | −18—— | −16*—— | −4.6—— | −4.2—— | −3.2—— | −5.1*—— | −2.2—— | −5.1—— | −3.3—— | −4.1r−4.1*—— | −5.3r−5.3—— | |
| Interest and finance income | 0.2+35178%— | 0.1+35149%— | 0.1+62837%— | 0.1*+49433%— | 0.0−17.9%— | 0.0−16.9%— | 0.0−13.1%— | 0.0*+16.1%— | 0.0+36.6%— | 0.0—— | 0.0—— | 0.0*—— | 0.0—— | |
| Interest expense and finance costs | — | — | — | 0.0*−70.4%— | 0.0−44.8%— | 0*−100%— | 0.0−98.8%— | 0.0*−89.4%— | 0.0−37.6%— | 0.0—— | 0.0—— | 0.0*—— | 0.0—— | |
| Other non-operating income (expense) | 2.8—— | 0.0—— | 0.2—— | 2.8*—— | −0.3—— | −0.1—— | −8.9—— | −0.8*−8302%— | −0.2−1616%— | −0.1—— | −0.0—— | 0.0r−0.0*—— | 0.0r0.0—— | |
| Income before tax | — | −6.7—— | −18—— | — | — | −4.3—— | −12—— | — | — | — | — | — | — | |
| Income tax | — | — | — | 0.2*—— | 0*—— | 0*—— | 0—— | 0*—— | 0—— | 0—— | 0—— | 0*—— | 0—— | |
| Net income including minority interests | −43—— | −6.8*—— | −18—— | −13*—— | −4.9*—— | −4.3*—— | −12—— | −5.9*—— | −2.3*—— | −5.2*—— | −3.3—— | −4.1*—— | −5.3*—— | |
| Net income attributable to shareholders | −43—— | −6.8—— | −18—— | −13*—— | −4.9—— | −4.3—— | −12—— | −5.9*—— | −2.3—— | −5.2—— | −3.3—— | −4.1*—— | −5.3—— | |
| Earnings per share, basic | — | -7.17—— | -21.28—— | — | -5.82—— | -5.13—— | -70.16r-2.51—— | — | -146.06r-0.16—— | -680.23r-0.74—— | -21.35r-0.65—— | — | -48.44r-1.68—— | |
| Earnings per share, diluted | — | -7.17—— | -21.28—— | — | -5.82—— | -5.13—— | -70.16r-2.51—— | — | -146.06r-0.16—— | -680.23r-0.74—— | -21.35r-0.65—— | — | -48.44r-1.68—— | |
| Shares, weighted average (basic) | 1.0+14.8%— | 1.0+14.8%— | 0.9+432%— | — | 0.8+5146%— | 0.8r0.8+10825%— | 0.2r4.8+10.5%— | — | 0.0r15−85.5%— | 0.0r7.1—— | 0.2r5.1—— | — | 0.1r3.2—— | |
| Shares, weighted average (diluted) | 1.0+14.8%— | 1.0+14.8%— | 0.9+432%— | — | 0.8+5146%— | 0.8r0.8+10825%— | 0.2r4.8+10.5%— | — | 0.0r15−85.5%— | 0.0r7.1—— | 0.2r5.1—— | — | 0.1r3.2—— | |
| Balance sheet | ||||||||||||||
| Cash and cash equivalents | 8.4—5.6% | 8.4+13.7%5.6% | 13+10.9%8.2% | 18+207%11.0% | 2.8+51.2%54.3% | 7.4+120%89.2% | 12+135%87.7% | 5.8+110%79.7% | 1.9−74.8%47.7% | 3.4—69.5% | 4.9—67.4% | 2.8—53.5% | 7.5—72.9% | |
| Other current assets | 2.3—1.5% | 2.3+227%1.5% | 1.6+40.1%1.0% | 0.9−28.3%0.6% | 1.7−0.5%32.8% | 0.7−33.1%8.4% | 1.2−36.0%8.7% | 1.3−24.0%17.6% | 1.7−10.2%43.8% | 1.0—21.4% | 1.8—24.7% | 1.7—32.6% | 1.9—18.8% | |
| Current assets | 11—7.0% | 11+29.1%7.0% | 17+28.4%10.7% | 22+210%13.5% | 4.8+31.5%90.9% | 8.2+87.9%99.7% | 13+94.3%98.9% | 7.1+59.2%97.2% | 3.6−61.5%91.8% | 4.4—90.9% | 6.7—92.1% | 4.5—86.2% | 9.4—91.6% | |
| Property, plant and equipment | 0.3—0.2% | 0.3+1208%0.2% | 0.3+809%0.2% | 0.4+619%0.2% | 0.0−67.6%0.4% | 0.0−61.8%0.3% | 0.0−58.7%0.3% | 0.1−57.3%0.7% | 0.1−59.7%1.6% | 0.1—1.3% | 0.1—1.3% | 0.1—2.3% | 0.2—1.5% | |
| Right-of-use (leased) assets | — | — | — | — | — | — | — | 0.0−92.2%0.5% | 0.2−74.5%3.8% | 0.3—5.4% | 0.4—5.1% | 0.5—9.3% | 0.6—5.8% | |
| Goodwill | 26—17.0% | 26—17.0% | 26—16.4% | 26—15.9% | — | — | — | — | — | — | — | — | — | |
| Other intangible assets | 114—75.7% | 114—75.7% | 114—72.7% | 114—70.4% | — | — | — | — | — | — | — | — | — | |
| Total assets | 151—100% | 151+1727%100% | 157+1091%100% | 162+2126%100% | 5.2+32.8%100% | 8.3+71.3%100% | 13+81.0%100% | 7.3+41.1%100% | 3.9−61.5%100% | 4.8—100% | 7.3—100% | 5.2—100% | 10—100% | |
| Accounts payable | 4.7—3.1% | 4.7+199%3.1% | 5.3+111%3.4% | 3.5+29.0%2.2% | 3.0+39.2%56.8% | 1.6−52.2%18.9% | 2.5+6.0%19.0% | 2.7−11.2%37.1% | 2.1−58.5%54.2% | 3.3—67.9% | 2.4—32.5% | 3.1—59.0% | 5.1—50.2% | |
| Current liabilities | 5.4—3.6% | 5.4+245%3.6% | 5.4+114%3.4% | 3.5+26.1%2.2% | 3.0+29.9%56.8% | 1.6−55.3%18.9% | 2.5−7.3%19.0% | 2.8−20.6%38.0% | 2.3−59.2%58.0% | 3.5—72.6% | 2.7—37.1% | 3.5—67.5% | 5.6—54.7% | |
| Lease liabilities (non-current) | — | — | — | — | — | — | — | — | — | — | — | 0.0—0.7% | 0.2—1.9% | |
| Non-current liabilities | 7.3—4.8% | 7.3+1210%4.8% | 7.3+1753%4.6% | 7.0+7.4%4.3% | 0.8—15.9% | 0.6—6.7% | 0.4—3.0% | 6.5+16983%89.7% | — | — | — | 0.0—0.7% | — | |
| Total liabilities | 13—8.4% | 13+497%8.4% | 13+336%8.0% | 11+12.9%6.5% | 3.8+66.4%72.7% | 2.1−39.5%25.6% | 2.9+7.2%22.0% | 9.3+164%128% | 2.3−60.5%58.0% | 3.5—72.6% | 2.7—37.1% | 3.5—68.3% | 5.8—56.6% | |
| Retained earnings | −122—−81.1% | −122—−81.1% | −116—−73.6% | −98—−60.3% | −84—−1615% | −80—−962% | −75—−571% | −63—−866% | −57—−1455% | −55—−1139% | −50—−682% | −46—−898% | −42—−414% | |
| Shareholders' equity | −28—−18.3% | −28−550%−18.3% | 1.3−87.8%0.8% | 10—6.4% | 1.4−13.7%27.3% | 6.1+365%74.4% | 10+125%78.0% | −2.0−223%−27.7% | 1.7−62.8%42.0% | 1.3—27.4% | 4.6—62.9% | 1.6—31.7% | 4.4—43.4% | |
| Total liabilities and equity | 151—100% | 151+1727%100% | 157+1091%100% | 162+2126%100% | 5.2+32.8%100% | 8.3+71.3%100% | 13+81.0%100% | 7.3+41.1%100% | 3.9−61.5%100% | 4.8—100% | 7.3—100% | 5.2—100% | 10—100% | |
| Shares outstanding | 1.0—— | 1.0+21.3%— | 0.9−96.1%— | 0.9+2395%— | 0.8−95.2%— | 0.8−88.5%— | 23+302%— | 0.0r1.0+93.3%— | 17+61.5%— | 7.3—— | 5.8—— | 0.0r0.6—— | 11—— | |
| Cash-flow statement | ||||||||||||||
| Depreciation and amortization | 0.1+82.9%— | 0.0+78.1%— | 0.0+78.1%— | 0.0*+333%— | 0.0−70.2%— | 0.0−58.5%— | 0.0−58.2%— | 0.0*−67.3%— | 0.0−48.6%— | 0.0—— | 0.0—— | 0.0*—— | 0.0—— | |
| Share-based compensation | — | — | — | 0.1*−63.3%— | 0.1*−34.3%— | 0.1*−88.5%— | 0.2−13.9%— | 0.2*−45.6%— | 0.2*−47.9%— | 1.1*—— | 0.2—— | 0.3*—— | 0.4*—— | |
| Cash from operating activities | −23—— | −5.4*—— | −5.0—— | −8.1*—— | −4.1*—— | −4.2*—— | −3.1—— | −3.1*—— | −3.9*—— | −2.3*—— | −3.9—— | −5.7*—— | −3.5*—— | |
| Capital expenditure | — | — | — | — | — | — | — | −0.0*—— | −0.0*—— | −0.0*—— | −0.0—— | 0*—— | −0.0*—— | |
| Cash from investing activities | — | — | — | — | — | — | — | −0.0*—— | −0.0*—— | −0.0*—— | −0.0—— | 0*—— | −0.0*—— | |
| Shares issued | — | — | — | 0.0*−100.0%— | 0*−100%— | 0*−100%— | 8.9+45.5%— | 7.1*+624%— | 2.4*−66.3%— | 0.8*—— | 6.1—— | 1.0*—— | 7.3*—— | |
| Cash from financing activities | — | — | — | 23*+227%— | −0.5*−119%— | 0*−100%— | 8.9+45.5%— | 7.1*+624%— | 2.4*−66.9%— | 0.8*—— | 6.1—— | 1.0*—— | 7.4*—— | |
| Change in cash | 1.0−74.9%— | −4.5*—— | −5.0−186%— | 15*+281%— | −4.5*—— | −4.2*—— | 5.8+168%— | 3.9*—— | −1.5*−138%— | −1.6*—— | 2.1—— | −4.7*—— | 3.9*—— | |
| Report | Worked out | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q | |
* Worked out from reported figures: a quarter the company states only within a year-to-date figure (cash flows are reported that way), or the fourth quarter as the fiscal year minus the first nine months.
r Changed after it was first reported (a restatement, a reclassification or a later report's rounding); hover for the first value and filing, or show every figure as first reported: what investors could read at the time, without look-ahead. Restatements across companies
Build a DCF model from these statements: revenue, margins, tax, depreciation, capital spending, working capital, debt, cash and shares filled in from the annual reports, every assumption yours.
Source: SEC EDGAR filings (XBRL) · as of Jun 30, 2026. A fiscal year is listed under the calendar year it mostly falls in; quarters are numbered within the company's fiscal year. Balance-sheet figures are those at the end of each period. Payments in the cash-flow statement are negative
Events at TransCode Therapeutics, Inc.#
What the company reported to the SEC within four business days (Form 8-K), newest first.
Warning signs in the last three years
Delisting notice 3 · Debt called early 1 · Acquisition or sale completed 1 · Directors and officers 3 · Material agreement 6 · New debt 1 · Unregistered share sale 3 · Shareholder rights changed 5 · Bylaws or fiscal year changed 5 · Shareholder vote 2
| Filed | What happened | Filing |
|---|---|---|
| Debt called earlyMaterial agreement | 8-K | |
| Directors and officers | 8-K | |
| Shareholder rights changedBylaws or fiscal year changed | 8-K | |
| Shareholder vote | 8-K | |
| Shareholder rights changedBylaws or fiscal year changed | 8-K | |
| Delisting notice | 8-K/A | |
| Delisting notice | 8-K | |
| Material agreementNew debtUnregistered share sale | 8-K | |
| Unregistered share saleShareholder rights changedBylaws or fiscal year changed | 8-K | |
| Directors and officers | 8-K | |
| Shareholder rights changedBylaws or fiscal year changed | 8-K | |
| Material agreement | 8-K/A | |
| Acquisition or sale completedDirectors and officersMaterial agreementUnregistered share saleShareholder rights changedBylaws or fiscal year changed | 8-K | |
| Material agreement | 8-K/A | |
| Material agreement | 8-K | |
| Shareholder vote | 8-K | |
| Delisting notice | 8-K |
Source: SEC EDGAR, Form 8-K item numbers · as of Oct 1, 2026
Acquisitions and funding#
1 acquisitions, $140 M paid where reported
Businesses it acquired
| Acquired | Acquisition date | Completion | Price | Stake | Source |
|---|---|---|---|---|---|
| ABCJ, LLC | 2025 | — | $140 M | 100% | Annual report |
Private share sales · funding history
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Dec 2024 | $8 M | Private placement after listing | $2 to $10 million | 6 | equity, options | SEC |
Source: Annual reports and Form D notices filed with the SEC; Wikidata. Acquisitions are the businesses the company reports as acquired in its newest annual report, with the price paid. Funding rounds do not name their investors; the investors listed are those Wikidata records.
How TransCode Therapeutics, Inc. compares in Biotechnology
- Market cap$3 M · higher than 2% of 726
- Price / book0.3× · lower than 97% of 534
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| TransCode Therapeutics, Inc.🇺🇸 | $3 M | — | — | — |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Questions people ask
Compare head to head
Similar companies by size and industry
- Regenxbio Inc.$513 M
- Pharmicell Co., Ltd.$514 M
- Pulike Biological Engineering, Inc.$524 M
- Contineum Therapeutics, Inc.$534 M
- Entera Bio Ltd.$543 M
- Arvinas, Inc.$544 M
Sources and freshness
- Market cap:
- Aug 1, 2026
- Annual results:
- For year ending December-2025
- Balance sheet:
- As of December-2025
- Employees:
- As of April 3, 2026
- Profile updated:
- Nov 20, 2026
Figures from Market data, SEC filing, value.today research, SEC annual report; financial statements from SEC filings.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at TransCode Therapeutics, Inc.? Verify and update this profile — free
Show TransCode Therapeutics, Inc.'s ranking or a chart on your website Get the badge
The badge updates itself as the ranking changes.